Drug Safety and Risk Management Advisory Committee; Amendment of Notice, 2509 [E8-490]
Download as PDF
<![CDATA[
2509
Federal Register / Vol. 73, No. 10 / Tuesday, January 15, 2008 / Notices
Committee Name
Tentative Date of Meeting(s)
Advisory Committee
10-Digit Information
Line Code
Molecular and Clinical Genetics Panel
May 6–7, November 11–12
3014510231
Neurological Devices Panel
March 25–26, June 3–4, September 23–24, November 6–
7
3014512513
Obstetrics and Gynecology Devices Panel
April 17–18, June 19–20, August 14–15, October 16–17,
December 11–12
3014512524
Ophthalmic Devices Panel
February 21–22, May 15–16, September 18–19, November 20–21
3014512396
Orthopedic and Rehabilitation Devices Panel
April 21–22, June 16–17, August 18–19, October 20–21,
December 8–9
3014512521
Radiological Devices Panel
April 15–16, August 12, November 4
3014512526
National Mammography Quality Assurance Advisory Committee
October 13–14
3014512397
Technical Electronic Product Radiation Safety Standards
Committee
October 8
3014512399
July 22, December 2
3014510564
March day to be announced
3014512548
August 12–13
3014512559
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION
Food Advisory Committee
CENTER FOR VETERINARY MEDICINE
Veterinary Medicine Advisory Committee
National Center for Toxicological Research (NCTR)
Science Advisory Board to NCTR
Dated: January 7, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–567 Filed 1–14–08; 8:45 am]
Dated: January 7, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–490 Filed 1–14–08; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Fishers Lane, Rockville, MD 20857,
301–827–7001, FAX: 301–827–6776, email: Teresa.Watkins@fda.hhs.gov, or
FDA Advisory Committee Information
Line, 1–800–741–8138 (301–443–0572
in the Washington DC area), code
3014512535. Please call the Information
Line for up-to-date information on this
meeting.
Food and Drug Administration
SUPPLEMENTARY INFORMATION:
In the
Federal Register of December 11, 2007,
FDA announced that a meeting of the
Drug Safety and Risk Management
Advisory Committee would be held on
February 1, 2008. On page 70336, in the
second column, the first paragraph of
the Agenda portion of document is
amended to read as follows:
Agenda: The committee will discuss
the efficacy and safety of new drug
application (NDA) 22–054, INJECTAFER
(ferric carboxymaltose injection),
Luitpold Pharmaceuticals Inc., used for
the treatment of iron deficiency anemia
in postpartum patients or iron
deficiency anemia in patients with
heavy uterine bleeding.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Health Resources and Services
Administration
BILLING CODE 4160–01–S
Drug Safety and Risk Management
Advisory Committee; Amendment of
Notice
AGENCY:
Food and Drug Administration,
HHS.
rwilkins on PROD1PC63 with NOTICES
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of meeting of the Drug Safety
and Risk Management Advisory
Committee. This meeting was
announced in the Federal Register of
December 11, 2007 (72 FR 70336). The
amendment is being made to reflect a
change in the Agenda portion of the
document. There are no other changes.
FOR FURTHER INFORMATION CONTACT:
Teresa A. Watkins, Center for Drug
Evaluation and Research (HFD–21),
Food and Drug Administration, 5600
VerDate Aug<31>2005
17:48 Jan 14, 2008
Jkt 214001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notification of Exception to
Competition
Health Resources and Services
Administration, HHS.
AGENCY:
Notification of Exception to
Competition.
ACTION:
SUMMARY: The Health Resources and
Services Administration (HRSA) is
issuing a non-competitive program
expansion supplement to the National
Health Care for the Homeless Council
(NHCHC) to provide expanded training
and technical assistance to HRSAfunded grantees serving individuals
who are homeless.
Authority: This activity is under the
authority of the Public Health Service
Act, section 330(l).
E:\FR\FM\15JAN1.SGM
15JAN1
]]>Agencies
[Federal Register Volume 73, Number 10 (Tuesday, January 15, 2008)]
[Notices]
[Page 2509]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-490]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Drug Safety and Risk Management Advisory Committee; Amendment of
Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of meeting of the Drug Safety and Risk Management
Advisory Committee. This meeting was announced in the Federal Register
of December 11, 2007 (72 FR 70336). The amendment is being made to
reflect a change in the Agenda portion of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT: Teresa A. Watkins, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-
mail: Teresa.Watkins@fda.hhs.gov, or FDA Advisory Committee Information
Line, 1-800-741-8138 (301-443-0572 in the Washington DC area), code
3014512535. Please call the Information Line for up-to-date information
on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of December 11,
2007, FDA announced that a meeting of the Drug Safety and Risk
Management Advisory Committee would be held on February 1, 2008. On
page 70336, in the second column, the first paragraph of the Agenda
portion of document is amended to read as follows:
Agenda: The committee will discuss the efficacy and safety of new
drug application (NDA) 22-054, INJECTAFER (ferric carboxymaltose
injection), Luitpold Pharmaceuticals Inc., used for the treatment of
iron deficiency anemia in postpartum patients or iron deficiency anemia
in patients with heavy uterine bleeding.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: January 7, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-490 Filed 1-14-08; 8:45 am]
BILLING CODE 4160-01-S
